Details

Autor(en) / Beteiligte

• Howard, Robert
• Burns, Alistair
• Schneider, Lon

Titel

Antipsychotic prescribing to people with dementia during COVID-19

Ist Teil von

• Lancet neurology, 2020-11, Vol.19 (11), p.892-892

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• According to the Office of National Statistics, 17 316 patients died in England in April, 2020, with “dementia and Alzheimer's disease” recorded on their death certificate.3 This number of deaths was nearly three times more than expected, compared with the 5-year mean for April (appendix). AB reports being National Clinical Director for Dementia at the National Health Service England, and receiving personal fees from National Health Service England, personal fees from International Journal of Geriatric Psychiatry, personal fees from various lectures and talks, personal fees from occasional court reports, other from Driver and Vehicle Licensing Authority, outside the submitted work. LS reports grants and personal fees from Eli Lilly, personal fees from Avraham Pharmaceuticals, personal fees from Boehringer Ingelheim, grants and personal fees from Merck, personal fees from Neurim, personal fees from Neuronix, personal fees from Cognition, personal fees from Eisai, personal fees from Takeda, personal fees from vTv Therapeutics, grants and personal fees from Roche/Genentech, grants from Biogen, grants from Novartis, personal fees from Abbott, grants from Biohaven, grants from Washington University of St. Louis, grants from Dominantly Inherited Alzheimer Network Trial Unit of the National Institute on Aging, and personal fees from Samus, outside the submitted work.